title: Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
abstract: Monoamine oxidase (MAO) inhibitors were reported to have therapeutic value in several common neurodegenerative conditions owed to their diverse pharmacological functions in neuron survival. Rasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible MAO-B inhibitor in the treatment of Parkinson's disease (PD). It has been demonstrated to be neuroprotective in PD model systems by preventing the formation of reactive oxygen species derived from prevention of derived from oxidation of dopamine by MAO-B and via an antiapoptotic action, which appears to be independent of MAO-B inhibition and related to its embedded N-propargyl moiety. This review reflects on earlier and present evidence supporting a role for rasagiline as a neuroprotective molecule in the treatment of PD.
authors.affiliation: Eve Topf Centre of Excellence for Neurodegenerative Diseases and Department of Molecular Pharmacology, Technion-Rappaport Faculty of Medicine, Efron Street, P.O. Box 9697, Haifa, Israel.
authors.forename: Orly
authors.initials: O
authors.lastname: Weinreb
authors.forename: Tamar
authors.initials: T
authors.lastname: Amit
authors.forename: Peter
authors.initials: P
authors.lastname: Riederer
authors.forename: Moussa B H
authors.initials: MB
authors.lastname: Youdim
authors.forename: Silvia A
authors.initials: SA
authors.lastname: Mandel
mesh_terms: D000818:Animals; D006801:Humans; D007189:Indans / Q000737:chemistry / Q000494:pharmacology*; D008995:Monoamine Oxidase / Q000502:physiology*; D008996:Monoamine Oxidase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D018696:Neuroprotective Agents / Q000737:chemistry / Q000494:pharmacology*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000201:enzymology; D013329:Structure-Activity Relationship
chemical_list: D007189:Indans; D008996:Monoamine Oxidase Inhibitors; D018696:Neuroprotective Agents; C031967:rasagiline; D008995:Monoamine Oxidase